Migraine Drugs Linked to Higher Miscarriage Risk
A new observational study identifies a 40 percent increased risk of miscarriage for pregnancies exposed to anti-CGRP antibodies.
Updated on Oct. 12, 2026 in Pregnancy
Research published in JAMA Neurology suggests a correlation between anti-CGRP monoclonal antibodies and an increased risk of miscarriage. The study analyzed thousands of pregnancies from a commercially insured US population between 2018 and 2021.
Why it matters
Understanding the safety of common migraine treatments during the first 20 weeks of pregnancy is essential, as CGRPs are believed to play a significant role in early placental development and embryo implantation.
Researchers studied 7,579 pregnancies over a 20-week period to assess miscarriage outcomes. Exposure to anti-CGRP medications was compared against non-exposed patients, while propranolol was used as a control.
The players
JAMA Neurology
This is a peer-reviewed medical journal that publishes clinical research and advancements in the field of neurology.
The details
The analysis compared mothers with migraine diagnoses or triptan prescriptions to determine how specific treatments affect early pregnancy. While the results indicate a potential concern regarding placental development, the observational nature of the research means specific clinical causation remains under investigation.
Timeline
2018-2021: Data collection period for insurance patient records.
October 2026: Research findings were published in JAMA Neurology.
Culture Shift
This study marks a significant step in the ongoing clinical monitoring of CGRP-targeted monoclonal antibodies. It highlights a critical shift in how medical professionals balance chronic condition management with emerging safety data for expectant mothers.
Expectant mothers currently using migraine medications should consult with their healthcare providers regarding these findings. This study encourages a more cautious approach to prescribing anti-CGRP therapies during the first trimester of pregnancy.
The takeaway
Patients should discuss all medication plans with their obstetrician or neurologist to weigh the risks of untreated migraines against potential developmental concerns. Relying on observational studies requires professional interpretation to make informed medical decisions.
Further reading
Learn more about health guidelines during this time in the Pregnancy section.
Source note: This article includes information reported by ScienceAlert.
